Journal: eBioMedicine
Article Title: A humanised ACE2, TMPRSS2, and FCGRT mouse model reveals the protective efficacy of anti-receptor binding domain antibodies elicited by SARS-CoV-2 hybrid immunity
doi: 10.1016/j.ebiom.2025.105619
Figure Lengend Snippet: Functionality of hFcRn in hACE2-TMPRSS2-FCGRT TKI mice . (a) Pharmacokinetics of 1C3-YTE mAb, 1C3-WT mAb, and polyclonal human IgG (pAb) in TKI and DKI mice. Groups of treatment-naïve mice were injected intraperitoneally with 1 mg/kg mAbs or pAbs and bled at 3, 24, 72, 168, 336, and 504 h post-dose. Each mouse was bled at a maximum of two time points. Data are presented as the mean ± SEM of 3–8 mice/group/time point, pooled from two independent experiments. Group means at day 21 were compared by mixed-effect analysis and Šídák's correction. The open and filled bars represent DKI and TKI, respectively. (b) Half-life of 1C3-YTE, 1C3-WT, and pAbs in TKI and DKI mice. Group means were compared by mixed-effect analysis and Šídák's correction. The open and filled bars represent DKI and TKI, respectively. (c) Experimental protocol for the data shown in (d and e). TKI and DKI mice were injected intraperitoneally (d) or intranasally (e) with 0.5 mg/kg of 1C3-YTE, 1C3-WT, or an anti-SARS-CoV-1 hIgG (negative control). One day later, mice were inoculated intranasally with Omicron BA.2 (10 4 PFU in 30 μl) and nasal turbinate (nt) and lungs were harvested on day 2 post-infection. (d) and (e) RT-qPCR analysis of Omicron BA.2 subgenomic (sg) RNA and plaque assay of infectious virus in the nt and/or lungs of TKI and DKI mice on day 2 post-infection. Data are presented as the mean ± SEM of 6–12 mice/group, pooled from two independent experiments. Circles represent individual mice and dotted lines indicate the limit of detection. Group means were compared by the Kruskal–Wallis and Dunn's multiple comparisons tests. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.
Article Snippet: DKI mice (hACE2 and hTMPRSS2) and TKI mice (hACE2, hTMPRSS2, and hFCGRT; generated as described below) were bred at Synbal (San Diego, CA) and LJI, and housed in a specific pathogen-free facility under controlled temperature, humidity, and light (12 h on/off).
Techniques: Drug discovery, Injection, Negative Control, Infection, Quantitative RT-PCR, Plaque Assay, Virus